Document Classification

Section Type: METHODS

Text: Between January 1988 and December 1989, 169 patients were divided randomly into the following groups : group I, HFX RT with 1. 2 Gy twice daily to a total dose of 64. 8 Gy (n = 61) ; group II, same HFX RT with CHT consisting of 100 mg of carboplatin (CBDCA) on days 1 and 2 and 100 mg of etoposide (VP-16) on days 1 to 3 of each week during the RT course (n = 52) ; and group III, same HFX RT with CHT consisting of 200 mg of CBDCA on days 1 and 2 and 100 mg of VP-16 on days 1 to 5 of the first, third, and fifth weeks of the RT course (n = 56).